Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
2.500
+0.050 (2.04%)
Oct 5, 2026, 2:58 PM EDT - Market open
Voyager Therapeutics Employees
Voyager Therapeutics had 141 employees as of December 31, 2025. The number of employees decreased by 31 or -18.02% compared to the previous year.
Employees
141
Change (1Y)
-31
Growth (1Y)
-18.02%
Revenue / Employee
$244,390
Profits / Employee
-$764,028
Market Cap
154.04M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 141 | -31 | -18.02% | 141 | 0 |
| Dec 31, 2024 | 172 | 10 | 6.17% | 172 | 0 |
| Dec 31, 2023 | 162 | 37 | 29.60% | 162 | 0 |
| Dec 31, 2022 | 125 | 24 | 23.76% | 125 | 0 |
| Dec 31, 2021 | 101 | -78 | -43.58% | 101 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Humacyte | 184 |
| Codexis | 146 |
| Tonix Pharmaceuticals Holding | 142 |
| Molecular Partners AG | 134 |
| Acumen Pharmaceuticals | 61 |
| PepGen | 57 |
| Compass Therapeutics | 39 |
| NovaBridge Biosciences | 30 |
VYGR News
- 26 days ago - Voyager Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 4 weeks ago - Voyager to Present at Upcoming Investor Conferences - GlobeNewsWire
- 1 month ago - Voyager Therapeutics reports Q2 EPS (40c), consensus (51c) - TheFly
- 2 months ago - Voyager Therapeutics Quarterly report: Q2 2026 - Filings
- 2 months ago - Voyager Therapeutics Earnings release: Q2 2026 - Filings
- 2 months ago - Voyager Therapeutics presents six-month toxicology data for VY1706 - TheFly
- 2 months ago - Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 - GlobeNewsWire
- 3 months ago - Voyager's Tau-Targeted Gene Therapy VY1706 for Alzheimer's Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026 - GlobeNewsWire